Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism

Acetylation, a key component in post-translational modification regulated by HATs and HDACs, is relevant to many crucial cellular contexts in organisms. Based on crucial pharmacophore patterns and the structure of targeted proteins, HAT inhibitors are designed and modified for higher affinity and be...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medicinal chemistry 2019-09, Vol.178, p.259-286
Hauptverfasser: Huang, Mengyuan, Huang, Jiangkun, Zheng, Yongcheng, Sun, Qiu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 286
container_issue
container_start_page 259
container_title European journal of medicinal chemistry
container_volume 178
creator Huang, Mengyuan
Huang, Jiangkun
Zheng, Yongcheng
Sun, Qiu
description Acetylation, a key component in post-translational modification regulated by HATs and HDACs, is relevant to many crucial cellular contexts in organisms. Based on crucial pharmacophore patterns and the structure of targeted proteins, HAT inhibitors are designed and modified for higher affinity and better bioactivity. However, there are still some challenges, such as cell permeability, selectivity, toxicity and synthetic availability, which limit the improvement of HAT inhibitors. So far, only few HAT inhibitors have been approved for commercialization, indicating the urgent need for more successful and effective structure-based drug design and synthetic strategies. Here, we summarized three classes of HAT inhibitors based on their sources and structural scaffolds, emphasizing on their synthetic methods and structure–activity relationships and molecular mechanisms, hoping to facilitate the development and further application of HAT inhibitors. [Display omitted] •Three classes of HAT inhibitors were summarized based on their sources and structural scaffolds.•The review focuses on synthetic approaches and modifications with biological results.•Overview of the protein active sites and mechanistic proposals.
doi_str_mv 10.1016/j.ejmech.2019.05.078
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2242153572</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0223523419304969</els_id><sourcerecordid>2242153572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-f79e528a950bf4f96dcc0330498b9e9cbd5263b86a7f70cde045543e28e946b23</originalsourceid><addsrcrecordid>eNp9kE1r3DAQhkVpaDZp_0EpOvZQu_qwZKuHQghNUwjkkpyFLI9ZLba01cgb9t_Xy6Y99jQwPO98PIR85KzmjOuvuxp2M_htLRg3NVM1a7s3ZMNb3VVSqOYt2TAhZKWEbC7JFeKOMaY0Y-_IpeTcKK7NhrzcBywpAnUeynEq2UUcITsEGuI29KGkjN_oTaTpAPkQ4GXtUzzGsgUM-IViyYsvS4bK-RIOoRxphsmVkCJuw566ONA5TeCXyWV6OtjFgPN7cjG6CeHDa70mz3c_nm7vq4fHn79ubx4qL7Uo1dgaUKJzRrF-bEajB--ZlKwxXW_A-H5QQsu-064dW-YHYI1SjQTRgWl0L-Q1-Xyeu8_p9wJY7BzQwzS5CGlBK0QjuJKqPaHNGfU5IWYY7T6H2eWj5cyelNudPSu3J-WWKbsqX2OfXjcs_QzDv9Bfxyvw_QzA-udqMFv0AaKHIWTwxQ4p_H_DH66Il04</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2242153572</pqid></control><display><type>article</type><title>Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Huang, Mengyuan ; Huang, Jiangkun ; Zheng, Yongcheng ; Sun, Qiu</creator><creatorcontrib>Huang, Mengyuan ; Huang, Jiangkun ; Zheng, Yongcheng ; Sun, Qiu</creatorcontrib><description>Acetylation, a key component in post-translational modification regulated by HATs and HDACs, is relevant to many crucial cellular contexts in organisms. Based on crucial pharmacophore patterns and the structure of targeted proteins, HAT inhibitors are designed and modified for higher affinity and better bioactivity. However, there are still some challenges, such as cell permeability, selectivity, toxicity and synthetic availability, which limit the improvement of HAT inhibitors. So far, only few HAT inhibitors have been approved for commercialization, indicating the urgent need for more successful and effective structure-based drug design and synthetic strategies. Here, we summarized three classes of HAT inhibitors based on their sources and structural scaffolds, emphasizing on their synthetic methods and structure–activity relationships and molecular mechanisms, hoping to facilitate the development and further application of HAT inhibitors. [Display omitted] •Three classes of HAT inhibitors were summarized based on their sources and structural scaffolds.•The review focuses on synthetic approaches and modifications with biological results.•Overview of the protein active sites and mechanistic proposals.</description><identifier>ISSN: 0223-5234</identifier><identifier>EISSN: 1768-3254</identifier><identifier>DOI: 10.1016/j.ejmech.2019.05.078</identifier><identifier>PMID: 31195169</identifier><language>eng</language><publisher>France: Elsevier Masson SAS</publisher><subject>Drug design ; Drug synthesis ; Epigenetics ; Histone acetyltransferase inhibitors ; Structure-activity relationship</subject><ispartof>European journal of medicinal chemistry, 2019-09, Vol.178, p.259-286</ispartof><rights>2019 Elsevier Masson SAS</rights><rights>Copyright © 2019 Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-f79e528a950bf4f96dcc0330498b9e9cbd5263b86a7f70cde045543e28e946b23</citedby><cites>FETCH-LOGICAL-c362t-f79e528a950bf4f96dcc0330498b9e9cbd5263b86a7f70cde045543e28e946b23</cites><orcidid>0000-0001-5122-2226</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ejmech.2019.05.078$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31195169$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Huang, Mengyuan</creatorcontrib><creatorcontrib>Huang, Jiangkun</creatorcontrib><creatorcontrib>Zheng, Yongcheng</creatorcontrib><creatorcontrib>Sun, Qiu</creatorcontrib><title>Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism</title><title>European journal of medicinal chemistry</title><addtitle>Eur J Med Chem</addtitle><description>Acetylation, a key component in post-translational modification regulated by HATs and HDACs, is relevant to many crucial cellular contexts in organisms. Based on crucial pharmacophore patterns and the structure of targeted proteins, HAT inhibitors are designed and modified for higher affinity and better bioactivity. However, there are still some challenges, such as cell permeability, selectivity, toxicity and synthetic availability, which limit the improvement of HAT inhibitors. So far, only few HAT inhibitors have been approved for commercialization, indicating the urgent need for more successful and effective structure-based drug design and synthetic strategies. Here, we summarized three classes of HAT inhibitors based on their sources and structural scaffolds, emphasizing on their synthetic methods and structure–activity relationships and molecular mechanisms, hoping to facilitate the development and further application of HAT inhibitors. [Display omitted] •Three classes of HAT inhibitors were summarized based on their sources and structural scaffolds.•The review focuses on synthetic approaches and modifications with biological results.•Overview of the protein active sites and mechanistic proposals.</description><subject>Drug design</subject><subject>Drug synthesis</subject><subject>Epigenetics</subject><subject>Histone acetyltransferase inhibitors</subject><subject>Structure-activity relationship</subject><issn>0223-5234</issn><issn>1768-3254</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kE1r3DAQhkVpaDZp_0EpOvZQu_qwZKuHQghNUwjkkpyFLI9ZLba01cgb9t_Xy6Y99jQwPO98PIR85KzmjOuvuxp2M_htLRg3NVM1a7s3ZMNb3VVSqOYt2TAhZKWEbC7JFeKOMaY0Y-_IpeTcKK7NhrzcBywpAnUeynEq2UUcITsEGuI29KGkjN_oTaTpAPkQ4GXtUzzGsgUM-IViyYsvS4bK-RIOoRxphsmVkCJuw566ONA5TeCXyWV6OtjFgPN7cjG6CeHDa70mz3c_nm7vq4fHn79ubx4qL7Uo1dgaUKJzRrF-bEajB--ZlKwxXW_A-H5QQsu-064dW-YHYI1SjQTRgWl0L-Q1-Xyeu8_p9wJY7BzQwzS5CGlBK0QjuJKqPaHNGfU5IWYY7T6H2eWj5cyelNudPSu3J-WWKbsqX2OfXjcs_QzDv9Bfxyvw_QzA-udqMFv0AaKHIWTwxQ4p_H_DH66Il04</recordid><startdate>20190915</startdate><enddate>20190915</enddate><creator>Huang, Mengyuan</creator><creator>Huang, Jiangkun</creator><creator>Zheng, Yongcheng</creator><creator>Sun, Qiu</creator><general>Elsevier Masson SAS</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5122-2226</orcidid></search><sort><creationdate>20190915</creationdate><title>Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism</title><author>Huang, Mengyuan ; Huang, Jiangkun ; Zheng, Yongcheng ; Sun, Qiu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-f79e528a950bf4f96dcc0330498b9e9cbd5263b86a7f70cde045543e28e946b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Drug design</topic><topic>Drug synthesis</topic><topic>Epigenetics</topic><topic>Histone acetyltransferase inhibitors</topic><topic>Structure-activity relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Huang, Mengyuan</creatorcontrib><creatorcontrib>Huang, Jiangkun</creatorcontrib><creatorcontrib>Zheng, Yongcheng</creatorcontrib><creatorcontrib>Sun, Qiu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Huang, Mengyuan</au><au>Huang, Jiangkun</au><au>Zheng, Yongcheng</au><au>Sun, Qiu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism</atitle><jtitle>European journal of medicinal chemistry</jtitle><addtitle>Eur J Med Chem</addtitle><date>2019-09-15</date><risdate>2019</risdate><volume>178</volume><spage>259</spage><epage>286</epage><pages>259-286</pages><issn>0223-5234</issn><eissn>1768-3254</eissn><abstract>Acetylation, a key component in post-translational modification regulated by HATs and HDACs, is relevant to many crucial cellular contexts in organisms. Based on crucial pharmacophore patterns and the structure of targeted proteins, HAT inhibitors are designed and modified for higher affinity and better bioactivity. However, there are still some challenges, such as cell permeability, selectivity, toxicity and synthetic availability, which limit the improvement of HAT inhibitors. So far, only few HAT inhibitors have been approved for commercialization, indicating the urgent need for more successful and effective structure-based drug design and synthetic strategies. Here, we summarized three classes of HAT inhibitors based on their sources and structural scaffolds, emphasizing on their synthetic methods and structure–activity relationships and molecular mechanisms, hoping to facilitate the development and further application of HAT inhibitors. [Display omitted] •Three classes of HAT inhibitors were summarized based on their sources and structural scaffolds.•The review focuses on synthetic approaches and modifications with biological results.•Overview of the protein active sites and mechanistic proposals.</abstract><cop>France</cop><pub>Elsevier Masson SAS</pub><pmid>31195169</pmid><doi>10.1016/j.ejmech.2019.05.078</doi><tpages>28</tpages><orcidid>https://orcid.org/0000-0001-5122-2226</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0223-5234
ispartof European journal of medicinal chemistry, 2019-09, Vol.178, p.259-286
issn 0223-5234
1768-3254
language eng
recordid cdi_proquest_miscellaneous_2242153572
source Elsevier ScienceDirect Journals Complete
subjects Drug design
Drug synthesis
Epigenetics
Histone acetyltransferase inhibitors
Structure-activity relationship
title Histone acetyltransferase inhibitors: An overview in synthesis, structure-activity relationship and molecular mechanism
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T03%3A01%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Histone%20acetyltransferase%20inhibitors:%20An%20overview%20in%20synthesis,%20structure-activity%20relationship%20and%20molecular%20mechanism&rft.jtitle=European%20journal%20of%20medicinal%20chemistry&rft.au=Huang,%20Mengyuan&rft.date=2019-09-15&rft.volume=178&rft.spage=259&rft.epage=286&rft.pages=259-286&rft.issn=0223-5234&rft.eissn=1768-3254&rft_id=info:doi/10.1016/j.ejmech.2019.05.078&rft_dat=%3Cproquest_cross%3E2242153572%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2242153572&rft_id=info:pmid/31195169&rft_els_id=S0223523419304969&rfr_iscdi=true